Discrimination of primary and chronic cytomegalovirus infection based on humoral immune profiles in pregnancy
BACKGROUNDMost humans have been infected with cytomegalovirus (CMV) by midlife without clinical signs of disease. However, in settings in which the immune system is undeveloped or compromised, the virus is not adequately controlled and consequently presents a major infectious cause of both congenital disease during pregnancy as well as opportunistic infection in children and adults. With clear evidence that risk to the fetus varies with gestational age at the time of primary maternal infection, further research on humoral responses to primary CMV infection during pregnancy is needed.METHODSHere, systems serology tools were applied to characterize antibody responses to CMV infection in pregnant and nonpregnant women experiencing either primary or chronic infection.RESULTSWhereas strikingly different antibody profiles were observed depending on infection status, limited differences were associated with pregnancy status. Beyond known differences in IgM responses used clinically for identification of primary infection, distinctions observed in IgA and FcγR-binding antibodies and among antigen specificities accurately predicted infection status. Machine learning was used to define the transition from primary to chronic states and predict time since infection with high accuracy. Humoral responses diverged over time in an antigen-specific manner, with IgG3 responses toward tegument decreasing over time as typical of viral infections, while those directed to pentamer and glycoprotein B were lower during acute and greatest during chronic infection.CONCLUSIONIn sum, this work provides insights into the antibody response associated with CMV infection status in the context of pregnancy, revealing aspects of humoral immunity that have the potential to improve CMV diagnostics.FUNDINGCYMAF consortium and NIH NIAID.
Authors
- Jason S. McLellan (ORCID: https://orcid.org/0000-0003-3991-542X)
- Andrew P. Hederman
- Christopher Remmel (ORCID: https://orcid.org/0000-0002-4696-3692)
- Shilpee Sharma (ORCID: https://orcid.org/0000-0003-4645-9442)
- Arnaud Marchant (ORCID: https://orcid.org/0000-0003-0578-0467)
- Catherine Donner (ORCID: https://orcid.org/0009-0005-1946-4870)
- Piera d’Angelo (ORCID: https://orcid.org/0000-0003-0232-5071)
- Chiara Fornara (ORCID: https://orcid.org/0000-0002-8589-2647)
- Daniel Wrapp (ORCID: https://orcid.org/0000-0002-0538-9647)
- Daniele Lilleri (ORCID: https://orcid.org/0000-0001-7747-7622)
- Harini Natarajan (ORCID: https://orcid.org/0000-0002-9205-289X)
- Joshua A. Weiner (ORCID: https://orcid.org/0000-0003-1054-0628)
- Margaret E. Ackerman (ORCID: https://orcid.org/0000-0002-4253-3476)
- Milena Furione (ORCID: https://orcid.org/0000-0001-7328-1454)
- Marie‐Luce Delforge
Institutions
- Dartmouth College (US)
- Université Libre de Bruxelles (BE)
- Erasmus Hospital (BE)
- Policlinico San Matteo Fondazione (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- The University of Texas at Austin (US)
Publication Details
- Journal
- Journal of Clinical Investigation
- Published
- 2024-08-29
- DOI
- https://doi.org/10.1172/jci180560
- Citations
- 4
- Primary Topic
- Cytomegalovirus and herpesvirus research
- Type
- article
- Field-Weighted Citation Impact
- 1.55
Funders
- Sanofi
- Fonds De La Recherche Scientifique - FNRS
- National Institutes of Health